Duality Biotherapeutics, Inc.
Research Duality Biotherapeutics, Inc. (4ZB) on Bullrun: market cap EUR 2.23B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4ZB
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 2.23B
- Financial periodFY2025
- RevenueCNY 1.85B
- Revenue growth-4.6%
- Net income-CNY 2.59B
- Free cash flowCNY 180.86M
- Gross margin31.8%
Valuation Snapshot
latest market cap is EUR 2.23B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 1.85B | -CNY 2.59B | CNY 180.86M | 31.8% | -29.47 | CNY 1.28B | CNY 149.78M | CNY 2.43B |
| FY2024 | CNY 1.94B | -CNY 1.05B | CNY 254.60M | 40.4% | -12.63 | CNY 1.21B | CNY 5.29M | -CNY 2.02B |
| FY2023 | CNY 1.79B | -CNY 357.51M | CNY 780.43M | 76.1% | -4.3 | CNY 1.13B | CNY 5.32M | -CNY 1.12B |
| FY2022 | CNY 1.60M | -CNY 387.09M | -CNY 321.67M | 100.0% | -4.65 | CNY 375.97M | CNY 4.67M | -CNY 769.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-18 | EUR 2.23B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Duality Biotherapeutics, Inc.'s market cap?
Duality Biotherapeutics, Inc.'s market capitalization is EUR 2.23B.
What does Duality Biotherapeutics, Inc. do?
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs.